## 3 Therapeutic Potential of Exosomes in Different Diseases
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline
**Seen Cells** & **Study** & **Targeted Tissue/Cells** & **Mechanism** & **Reference** \\ \hline Lippopolysaccharide-mediated pneumococcal human dental & & Schwann cells & Promote the proliferation, migration and odontogenic differentiation of SCs & [40] \\ pull Sp Spent Cells & & & of SCs & \\ \hline Human Bone Marrow Mesenchymal Stromal Cells & in vitro and in vivo & Renal cells & Extracellular vesicles (EVs) derived from murine and/or human & \\  & (MSCs) & & BM-MSCs reversed the radiation damage to marrow hematopoietic cells & [41] \\  & & & cells both in vitro and in vivo. & \\ \hline Human Unbilical Cord blood Mesenchymal Stem & & & HUC-MSCs releasedosomes that transferred milk,1266 to & \\  & Cells (hUCB-MSCs) & & hepatocytes and subsequently produced a protective effect against & \\  & & & hepatic kit via regulating (GSK3)-mediated butyl/cell creation & \\  & & & signaling pathway & \\ \hline Human-induced Pluripot Stem Cells & in vitro and in vivo & Cardiomyocytes & t iPSC PC-derived EV is effective in the treatment of CHF, possibly, in & \\  & & & part, through their specific miRNA signature and the associated & \\  & & & stimulation of cardioprotective pathways & \\ \hline Induced Pluripot Stem Cells (PSC) & in vitro and in vivo & Cardiac cells & The TPC-derived EV is induced angiopicior, migratory, and & \\  & & & antiapoptotic properties in cardiac endothelial cells in vitro, and & \\  & & & induced superior infarct repair via vivo compared with NFCs & \\ \hline Human-induced Pluripot Stem Cells (PSCs) & in vitro & Human Mesenchymal Stem & Purified EVs secreted from both PFSCs, and young MSCskeletal & \\  & & & Cells (MSCs) & senescence-associated cellular phenotypes of aged MSCs through & \\  & & & reducing intracellular ROS level via theosomal transfer of PBMCs & \\ \hline Human Mesenchymal Stem Cells (MSCs) & in vitro and in vivo & Autoimmune uveocentitis & Inhibiting the migration of inflammatory cells and & [45] \\ \hline Bone marrow stromal cells (HMSCs) & In vitro & Bronopulmonary dysplasia & Paracrine manner via the release of immunocompromised factory to & [46] \\  & & & ameliorate the parenchymal and vascular injury & \\ \hline Exosomes derived from _Mowalteration_ & & & & \\  & & & & promote DC activation as well as generating an antibacterial T & \\  & & & & cell response & \\ \hline Human umbilical cord mesenchymal stem cells & & & & \\  & & & & \\ \hline \hline \end{tabular}
\end{table} 
Table 1: _Cont._Nucleic acids and proteins are naturally carried by exosomes making them potential vehicles for the intentional incorporation of proteins and nucleic acids for therapeutic purposes [49]. Synthetic nanoparticles, numerous small chemotherapeutic molecules, and natural compounds are other therapeutic molecules that are efficiently delivered via exosomes [49]. Altogether, these stacks of therapeutic cargos loaded into exosomes are delivered efficiently to host cells with diverse effects [50]. However, concerns are that exosomes may generate immune responses. Therefore, to overcome this challenge, certain factors must be taken into consideration such as the cell source and site of formation. Exosomes should be carefully selected from the donor cells. In recent times, clinical application and use of exosomes in therapeutics have grown rapidly. The targeted use of exosomes is one of the promising methods for treating cancer [51], and these applications have also been extended to other disease conditions such as soft tissues [52], cardiovascular disease [53], obesity [54], autoimmune diseases [55], and others. In summary, we can say that exosomes are potential carriers of minor interfering RNAs and have a great potential for clinical uses in treatments, and some of these useful applications will be discussed as follows.